HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA.

Abstract
Ceftaroline fosamil was approved in 2010 by the United States Food and Drug Administration (USA-FDA) for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP). After approval, several studies and case reports have described the postmarketing clinical experience with ceftaroline in ABSSSIs and CABP and in patients with invasive methicillin-resistant Staphylococcus aureus (MRSA) infections, many of whom had failed prior antibiotics. Successful clinical outcomes observed among the majority of these patients were supported by preapproval and postapproval in vitro surveillance of ceftaroline activity using breakpoint criteria that have been harmonized between the USA-FDA and CLSI. MIC90 values/percentage of strains susceptible to ceftaroline has remained stable over the period 2009-2012. Taken together, these postapproval studies support the use of ceftaroline for ABSSSI as well as CABP. Importantly, these data also suggest that ceftaroline can be effective in patients with serious invasive MRSA infections who have failed other therapies.
AuthorsMartin E Stryjewski, Ronald N Jones, G Ralph Corey
JournalDiagnostic microbiology and infectious disease (Diagn Microbiol Infect Dis) Vol. 81 Issue 3 Pg. 183-8 (Mar 2015) ISSN: 1879-0070 [Electronic] United States
PMID25583130 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Anti-Bacterial Agents
  • Cephalosporins
  • T 91825
Topics
  • Anti-Bacterial Agents (pharmacology, therapeutic use)
  • Cephalosporins (pharmacology, therapeutic use)
  • Community-Acquired Infections (drug therapy, microbiology)
  • Drug Approval
  • Humans
  • Methicillin-Resistant Staphylococcus aureus (drug effects, isolation & purification)
  • Microbial Sensitivity Tests
  • Product Surveillance, Postmarketing
  • Soft Tissue Infections (drug therapy, microbiology)
  • Staphylococcal Infections (drug therapy, microbiology)
  • Treatment Outcome
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: